

Status: Currently Official on 16-Feb-2025
 Official Date: Official as of 01-May-2018
 Document Type: USP Monographs
 DocId: GUID-BE435BBE-CE83-4F77-B71A-90D28236E1B6_3_en-US
 DOI: https://doi.org/10.31003/USPNF_M62290_03_01
 DOI Ref: c5h0s

© 2025 USPC
 Do not distribute

Pentazocine Injection

DEFINITION

Pentazocine Injection is a sterile solution of Pentazocine in Water for Injection, prepared with the aid of Lactic Acid. It contains NLT 95.0% and NMT 105.0% of the labeled amount of pentazocine ($C_{19}H_{27}NO$).

IDENTIFICATION

- **A.** The retention time of the pentazocine peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **B.** The UV spectrum of the pentazocine peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Solution A: 15 mM [sodium borate](#) in [water](#). Adjust with 10 N [sodium hydroxide](#) to a pH of 10.0.

Solution B: Methanol

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	85	15
15	15	85
20	15	85
21	85	15
25	85	15

Diluent: Methanol, [phosphoric acid](#), and [water](#) (500:1:500)

Standard solution: 0.024 mg/mL of [USP Pentazocine RS](#) in *Diluent*

Sample solution: Nominally 0.024 mg/mL of pentazocine from *Injection* in *Diluent*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 225 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm.

Column: 4.6-mm × 10-cm; 2.6-μm packing [L1](#)

Column temperature: 40°

Flow rate: 0.5 mL/min

Injection volume: 20 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 1.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of pentazocine ($C_{19}H_{27}NO$) in the portion of Injection taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of pentazocine from the *Sample solution*

r_s = peak response of pentazocine from the *Standard solution*

C_s = concentration of [USP Pentazocine RS](#) in the *Standard solution* (mg/mL)

C_u = nominal concentration of pentazocine in the *Sample solution* (mg/mL)

Acceptance criteria: 95.0%–105.0%

IMPURITIES

• ORGANIC IMPURITIES

Solution A, Solution B, Mobile phase, Diluent, and Chromatographic system: Proceed as directed in the Assay.

Sensitivity solution: 0.5 µg/mL of [USP Pentazocine RS](#) in *Diluent*

Standard solution: 0.002 mg/mL of [USP Pentazocine RS](#) in *Diluent*

Sample solution: Nominally 1 mg/mL of pentazocine from *Injection in Diluent*

System suitability

Samples: *Sensitivity solution* and *Standard solution*

Suitability requirements

Relative standard deviation: NMT 5.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of *Injection taken*:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of each impurity from the *Sample solution*

r_s = peak response of pentazocine from the *Standard solution*

C_s = concentration of [USP Pentazocine RS](#) in the *Standard solution* (mg/mL)

C_u = nominal concentration of pentazocine in the *Sample solution* (mg/mL)

Acceptance criteria: See [Table 2](#). The reporting threshold is 0.05%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Norpentazocine ^a	0.6	0.2
Pentazocine hydration product ^b	0.9	0.2
Pentazocine	1.0	—
Any unspecified impurity	—	0.2
Total impurities	—	0.5

^a (2R,6R,11R)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol.

^b (2R,6R,11R)-3-(3-Hydroxy-3-methylbutyl)-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methanobenzo[d]azocin-8-ol.

SPECIFIC TESTS

- **BACTERIAL ENDOTOXINS TEST (85):** NMT 5.8 USP Endotoxin Units/mg of pentazocine
- **pH (791):** 4.0–5.0
- **OTHER REQUIREMENTS:** It meets the requirements in *Injections and Implanted Drug Products (1)*.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in single-dose or multiple-dose containers, preferably of Type I glass. Store at 20°–25°.
- **USP REFERENCE STANDARDS (11):**

[USP Pentazocine RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
PENTAZOCINE INJECTION	Documentary Standards Support	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 42(5)

Current DocID: GUID-BE435BBE-CE83-4F77-B71A-90D28236E1B6_3_en-US

Previous DocID: GUID-BE435BBE-CE83-4F77-B71A-90D28236E1B6_1_en-US

DOI: https://doi.org/10.31003/USPNF_M62290_03_01

DOI ref: c5h0s